SAN FRANCISCO, May 13, 2015 /PRNewswire/ -- iRhythm Technologies, Inc., a leading digital healthcare solutions company focusing on the advancement of cardiac care, announced today the appointment of Derrick Sung, Ph.D. to the executive management team as executive vice president of global strategy and corporate development, effective May 1, 2015.
Dr. Sung will be responsible for driving new revenue opportunities by monetizing iRhythm's rapidly growing proprietary algorithms and patient database in mobile applications, analytics for consumer health monitoring and biomarker discovery. iRhythm's database, the largest in healthcare today, has efficiently curated and analyzed over 60 million hours of continuous electrocardiography and patient data. He will also drive global market development efforts for iRhythm's ZIO® Service, an FDA-cleared, outpatient cardiac monitor designed to improve patient compliance while maximizing diagnostic yield.
"Dr. Sung has the industry expertise, relationship network and deep insight into the future of healthcare that will make him a valuable addition to our leadership team," said Kevin King, president and chief executive officer of iRhythm Technologies. "He also has an outstanding reputation for growing organizations and developing pipeline opportunities through partnerships and licensing strategies. We feel very fortunate to have him on board to advance our growth opportunities across emerging markets in digital health, consumer wearables and big data analytics."
Prior to joining iRhythm, Dr. Sung was a senior equity research analyst at Sanford C. Bernstein & Company covering medical devices at leading cardiovascular and orthopedic companies including Johnson & Johnson, St. Jude, Abbott, Medtronic and Boston Scientific.
Previously, he served as the director of marketing and business development at Boston Scientific Neuromodulation where he led the commercialization of neurostimulation devices to treat a variety of therapeutic areas. Earlier, he spent four years at The Boston Consulting Group leading healthcare consulting projects ranging from licensing strategies, post-merger integrations, product development strategies, and operational effectiveness programs for biopharma and medical device companies. He began his career in the medical device field as a R&D engineer designing heart catheters for Guidant Corporation.
Dr. Sung received his Ph.D. in Bioengineering from the University of California, San Diego; his Master of Business Administration fromSan Diego State University, and his Bachelor of Science in Mechanical Engineering from Stanford University.
"I am very excited to join the iRhythm team," said Dr. Sung. "During my career, I have evaluated many companies in the healthcare field and I believe iRhythm is clearly becoming a disruptive force in cardiac digital health solutions. They are addressing dynamic and rapidly evolving markets with a sound business strategy and I am looking forward to contributing to its growing success."
The ZIO Service is the first long-term continuous monitoring service that is FDA-cleared and supported by extensive clinical data with peer-reviewed publications. The ZIO Service has been clinically proven to enhance clinical decision making and drive lower healthcare costs. Since its commercial launch in 2011, it has been used with over 300,000 patients at nearly 1,000 institutions in the U.S. Predictive analytics collected from Zio monitoring can be used to identify early and effective treatment options, prevent potential future medical emergencies and reduce readmissions.
About iRhythm Technologies, Inc.
iRhythm is a privately held digital healthcare solutions company that is a world leader in cardiac arrhythmia information. The company is combining
wearable biosensor devices with mobile and cloud-based technology to improve how heart arrhythmias are diagnosed and managed. iRhythm's digital health
technology and diagnostic support services provide clear, actionable information for physicians, and are clinically proven to enhance clinical decision
making and lower healthcare costs. Its flagship solution, the ZIO Service, offers a proven approach to long-term continuous monitoring that enables
diagnosis earlier in the clinical pathway to improve patient outcomes and reduce healthcare costs. For more information, please visit www.irhythmtech.com.
Media Contact
Amanda Breeding
Amanda.breeding@edelman.com
415-229-7649
SOURCE iRhythm Technologies, Inc.